Ro4938581

Ro4938581

Identifiers
IUPAC name 3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]diazepine
PubChem CID	11624499
IUPHAR/BPS	4299
ChemSpider	9799246
ChEMBL	CHEMBL1080588
Chemical and physical data
Formula	C13H8BrF2N5
Molar mass	352.14 g/mol
3D model (JSmol)	Interactive image
SMILES FC(F)C(N=C1)=C(N1C2=C3C=C(Br)C=C2)CN4C3=NC=N4
InChI InChI=1S/C13H8BrF2N5/c14-7-1-2-9-8(3-7)13-17-5-19-21(13)4-10-11(12(15)16)18-6-20(9)10/h1-3,5-6,12H,4H2 Key:AFJRYPJIKHMNGL-UHFFFAOYSA-N

Ro4938581 is a nootropic drug invented in 2009 by a team working for Hoffmann-La Roche, which acts as a subtype-selective inverse agonist at the α₅ subtype of the benzodiazepine binding site on the GABA_A receptor. It has good selectivity for the α₅ subtype and did not produce convulsant or anxiogenic effects in animal studies, making it a promising potential nootropic. Ro4938581 and a related derivative basmisanil (RG-1662, RO5186582) have subsequently been investigated for the alleviation of cognitive dysfunction in Down syndrome.